Neuronetics, Inc. announced that New York State Medicaid will start covering TMS services for adults with major depressive disorder (MDD) starting October 1, 2025, for fee-for-service members, and November 1, 2025, for Managed Care Plans. This decision will benefit nearly 1 million fee-for-service Medicaid individuals and over 4.4 million enrolled in Managed Care Organizations in New York State. NeuroStar Advanced Therapy, a non-drug, non-invasive treatment, has shown an 83% response rate and 62% remission rate for MDD patients. Neuronetics is dedicated to expanding access to TMS therapy and advocating for health policy updates to improve mental health treatment nationwide.

Read more at GlobeNewswire: New York State Medicaid Expands Coverage for TMS Therapy,